catalpol has been researched along with Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Cong, C; Hu, Y; Tao, L; Wang, Y; Yuan, X | 1 |
| Huang, XF; Jiang, ZZ; Li, CJ; Li, SJ; Li, XH; Sun, LX; Xu, DQ; Zhang, LY; Zhao, L | 1 |
2 other study(ies) available for catalpol and Cirrhosis
| Article | Year |
|---|---|
Catalpol Alleviates Ang II-Induced Renal Injury Through NF-κB Pathway and TGF-β1/Smads Pathway.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents; Cell Line; Disease Models, Animal; Fibrosis; Humans; Inflammation Mediators; Iridoid Glucosides; Kidney; Male; Mice; Mice, Inbred C57BL; Nephritis; NF-kappa B; Rats; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1 | 2022 |
Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-β1/TAK1 signaling pathway.
Topics: Animals; Fibrosis; Hand Strength; Inflammation; Iridoid Glucosides; Male; MAP Kinase Kinase Kinases; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle Strength; Muscle, Skeletal; Muscular Dystrophy, Duchenne; Signal Transduction; Transforming Growth Factor beta1 | 2021 |